Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DRTS Stock Forecast 2026-2027
$8.03
Current Price
$706.72M
Market Cap
Buy 3
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to DRTS Price Targets
+49.4%
To High Target of $12.00
+30.8%
To Median Target of $10.50
-37.7%
To Low Target of $5.00
DRTS Price Momentum
+5.1%
1 Week Change
+13.6%
1 Month Change
+212.5%
1 Year Change
+62.2%
Year-to-Date Change
-6.6%
From 52W High of $8.60
+221.2%
From 52W Low of $2.50
📊 TOP ANALYST CALLS
Did DRTS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Alpha Tau is one of their latest high-conviction picks.
Latest DRTS Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, DRTS has a bullish consensus with a median price target of $10.50 (ranging from $5.00 to $12.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $8.03, the median forecast implies a 30.8% upside. This outlook is supported by 3 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yi Chen at HC Wainwright & Co., projecting a 49.4% upside. Conversely, the most conservative target is provided by Jason Bednar at Piper Sandler, suggesting a 37.7% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DRTS Analyst Ratings
3
Buy
1
Hold
0
Sell
DRTS Price Target Range
Low
$5.00
Average
$10.50
High
$12.00
Current: $8.03
Latest DRTS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DRTS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 11, 2026 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $9.00 |
| Mar 10, 2026 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $12.00 |
| Mar 4, 2026 | Piper Sandler | Jason Bednar | Neutral | Downgrade | $5.00 |
| Feb 24, 2026 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $12.00 |
| Dec 10, 2025 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $7.00 |
| Nov 24, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
| Oct 22, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
| Sep 3, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
| Apr 29, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
| Mar 17, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
| Nov 22, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
| Oct 23, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
| Oct 11, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
| Aug 20, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
| Aug 15, 2024 | Piper Sandler | Jason Bednar | Overweight | Reiterates | $7.00 |
| Jun 26, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
| May 22, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
| May 16, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
| Mar 12, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
| Mar 8, 2024 | Piper Sandler | Jason Bednar | Overweight | Reiterates | $7.00 |
Alpha Tau Medical Ltd. (DRTS) Competitors
The following stocks are similar to Alpha Tau based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Alpha Tau Medical Ltd. (DRTS) Financial Data
Valuation Metrics
Market Cap
$706.72M
Enterprise Value
$642.04M
P/E Ratio
N/A
PEG Ratio
-18.9x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+10.3%
Current Ratio
7.5x
Debt/Equity
17.8x
ROE
-61.0%
ROA
-27.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Alpha Tau Medical Ltd. (DRTS) Business Model
About Alpha Tau Medical Ltd.
What They Do
Develops innovative alpha radiation therapies for cancer.
Business Model
The company operates as a clinical-stage biotechnology firm, focusing on the research, development, and commercialization of its proprietary Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT). It generates revenue through partnerships and collaborations with medical institutions for clinical trials and potential commercialization of its therapies targeting various solid tumors.
Additional Information
Founded in 2015 and based in Jerusalem, Alpha Tau Medical is addressing high unmet medical needs in oncology, particularly for cancers lacking effective standard treatments. The company is currently conducting clinical trials for multiple types of cancer, indicating a broad potential market for its therapeutic solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
121
CEO
Mr. Uzi Sofer
Country
Israel
IPO Year
2021
Website
www.alphatau.comAlpha Tau Medical Ltd. (DRTS) Latest News & Analysis
Latest News
Quick Summary
Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) will present clinical trial results of its Alpha DaRT® cancer therapy for pancreatic cancer at Digestive Disease Week 2026, a significant milestone for the company.
Why It Matters
Alpha Tau's presentation at a leading conference highlights significant progress in cancer treatment, potentially boosting investor confidence and interest in its stock due to increased visibility and credibility.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Alpha Tau Medical: 2026 Is The Breakthrough Year
26 days ago
Quick Summary
Alpha Tau Medical's Alpha DaRT technology shows promise for solid tumors, with key clinical trial results expected in 2026. The company faces a $42.3M loss but has cash for five to six quarters.
Why It Matters
Alpha Tau's promising Alpha DaRT technology and upcoming clinical trial results could significantly impact its market position, despite current losses and cash constraints posing dilution risks.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) announced CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference on March 18-19, 2026.
Why It Matters
Alpha Tau's presentation at a major conference may increase visibility and investor interest, potentially impacting stock performance and market perception of its cancer therapy.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Recent developments include Japanese marketing approval, a fifth U.S. trial approval, pancreatic cancer trial data presented at ASCO GI Symposium, and the first brain cancer treatment.
Why It Matters
The news highlights significant regulatory approvals and trial advancements, suggesting potential revenue growth and market expansion for the company, which could positively impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Alpha Tau Medical has received regulatory approval in Japan for its Alpha DaRT therapy to treat unresectable head and neck cancer, marking its first clinical authorization outside Israel.
Why It Matters
Alpha Tau Medical's approval in Japan for its innovative cancer therapy enhances market potential and credibility, signaling growth opportunities and increased investor confidence in the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT
1 month ago
Quick Summary
Japan has approved Alpha DaRT for treating head and neck cancer, marking its first market launch outside of Israel.
Why It Matters
Approval of Alpha DaRT in Japan expands its market potential, signaling growth opportunities for the company and potentially boosting stock value, while enhancing competition in cancer treatment.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About DRTS Stock
What is Alpha Tau Medical Ltd.'s (DRTS) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Alpha Tau Medical Ltd. (DRTS) has a median price target of $10.50. The highest price target is $12.00 and the lowest is $5.00.
Is DRTS stock a good investment in 2026?
According to current analyst ratings, DRTS has 3 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.03. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DRTS stock?
Wall Street analysts predict DRTS stock could reach $10.50 in the next 12 months. This represents a 30.8% increase from the current price of $8.03. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Alpha Tau Medical Ltd.'s business model?
The company operates as a clinical-stage biotechnology firm, focusing on the research, development, and commercialization of its proprietary Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT). It generates revenue through partnerships and collaborations with medical institutions for clinical trials and potential commercialization of its therapies targeting various solid tumors.
What is the highest forecasted price for DRTS Alpha Tau Medical Ltd.?
The highest price target for DRTS is $12.00 from Yi Chen at HC Wainwright & Co., which represents a 49.4% increase from the current price of $8.03.
What is the lowest forecasted price for DRTS Alpha Tau Medical Ltd.?
The lowest price target for DRTS is $5.00 from Jason Bednar at Piper Sandler, which represents a -37.7% decrease from the current price of $8.03.
What is the overall DRTS consensus from analysts for Alpha Tau Medical Ltd.?
The overall analyst consensus for DRTS is bullish. Out of 6 Wall Street analysts, 3 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $10.50.
How accurate are DRTS stock price projections?
Stock price projections, including those for Alpha Tau Medical Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 3:51 PM UTC